FilingReader Intelligence
Zhifei Biologics gains approval for tetanus vaccine clinical trial
June 21, 2025 at 05:11 AM UTC•By FilingReader AI
Chongqing Zhifei Biological Products (SZSE:300122) announced that its wholly-owned subsidiary, Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration to conduct clinical trials for its adsorbed tetanus vaccine (Notice No. 2025LP01605). The vaccine aims to prevent tetanus caused by Clostridium tetani infection.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Chongqing Zhifei Biological Products publishes news
Free account required • Unsubscribe anytime